Virginija Dambrauskaite, MD, PhD

Scientific Officer, Medical Research Unit, Health Directorate Directorate-General for Research & Innovation

European Commission

Health Innovations in Horizon 2020: the framework programme for research and innovation (2014-2020)

What Horizon 2020 is about

Responding to the economic crisis

Addressing people’s concerns

Strengthening the EU’s global position

Horizon 2020 timeline

From 30/11 Parliament and Council negotiations on the basis of the Commission proposals

On-going Parliament and Council negotiations on EU budget 2014-20 (including Horizon 2020)

By end 2013 Adoption of legislative acts by Parliament and Council on Horizon 2020

January 2014 Horizon 2020 starts; launch of first calls

2011

2012

2013

2014

More money for health research in times of austerity…?

Investing into the right research pays off:

Simpler, more personalised and cost-efficient technologies and treatments

Fewer ‘chronic patients’

New technologies, companies and markets

Higher share of radical innovation

Large returns on investment

New skilled jobs in high value-added sectors

Horizon 2020 and the Health, Demographic change and Wellbeing

challenge • Adapting to an ageing population

• Pursuing the path to more personalised medicine

• Harnessing and encouraging private sector capability

• Coordinating national efforts

• Expanding global cooperation

Health, Demographic change & wellbeing -the Commission's proposal for Horizon 2020

• Understanding health determinants

• Improving health promotion & disease prevention

• Developing effective screening programmes

• Improving the assessment of disease susceptibility

• Improving surveillance and preparedness

• Understanding disease

• Developing better preventive vaccines

• Improving diagnosis

• Using in-silico medicine for improving disease management and prediction

• Treating disease

• Transferring knowledge to clinical practice and scalable innovation actions

• Better use of health data

• Improving support for policy-making and regulation

• Active ageing, independent and assisted living

• Individual empowerment for self-management of health

• Promoting integrated care

• Optimising the efficiency and effectiveness of healthcare systems

• Reducing inequalities through evidence based decision making

• Dissemination of best practice, and innovative technologies and approaches.

The challenges ahead

• Cancer, chronic and degenerative diseases gain importance in the context of the ageing population

• More than 70% of healthcare spending on chronic diseases

• Wanted: ways of keeping our healthcare costs stable and our healthcare systems running

• EU must catch up with global health innovation leaders and keep its biomedical industry

The FP7 Health Programme

The largest multi-national fund:

to fund collaborative research

to fund international consortia and public-private partnerships

to fund excellent research and innovation in applied fields

involving leading players from Europe and across the globe

to tackle key health challenges which are too important or large for any one country to address alone

FP7 Health – state of play

3.3 billion EUR currently invested in 713 on-going projects

Some 2,900 organisations from 122 countries involved

Leading role in 6 international research consortia

1 billion EUR investment in Europe's largest public-private initiative for better and safer medicines

IMI is the world-largest Public-Private Partnership in health sciences research

Public Private Partnerships – the Innovative Medicines Initiative

10 regulators

17 patient

org

92 SMEs

508 Academic

& research

teams

341 EFPIA teams

603 million EUR IMI JU cash

contribution

600 million EUR EFPIA in kind contribution

~ 3500 researchers > 200 publications

Imaging

biomarkers:

the next

generation of

surrogate end

points?

Models for target

validation of

breast, prostate

and lung cancers

IMI State of play

Enhancing the innovation impact of results

Boosting the translation of health research projects' results into innovative applications for health (Inno-2).

Aimed at exploiting results from

projects funded within FP6 and FP7

Providing the viability of new methods, technologies, models or prototypes

Up to 5 patners and € 6 million

SMEs in the driving seat

Bridging the gap between successful prior research and the earlierst stage of a marketable innovation

€ 95 million

© Sergej Khackimullin #32849829 Source: Fotolia.com

FP7 Health – The concept of social innovation

To promote better quality of life and improved well-being for the elderly through innovative holistic approaches that meet social needs and create new social relationships

Examples: The development of a personalised strategy for reducing risks to

developing dementia.

The development of personalized electronic tools for effective

virtual rehabilitation environment after a stroke.

The development of an approach for health literacy for ageing

people, through the use of modern media and e-health

applications.

The development of social innovations to improve the quality of life

and well-being of older people.

Novel solutions to overcome bottlenecks to innovation

• Horizon2020 aims to optimise the efficiency and

effectiveness of health systems through the development of health technology assessment, health economics and innovative technologies and approaches in the healthcare sector.

Identification of the major bottlenecks to innovation in the area of research on health care systems

Finding solutions for creating a sustainable, cost effective and efficient health care system

Empowering people, driving change

• Behavioural change is critical to the prevention, management and treatment of many important health conditions and improves health outcomes, as well as cost savings to healthcare systems.

Finding the best approach to empower people to make the behavioural changes required

Scaling up innovative solutions

• Horizon 2020 aims to scale up innovative solutions to overcome the challenges and barriers to preventive health and to ensure that innovative and effective products reach the market.

Attracting stakeholders such as SMEs, industry and other sectors to innovation and ensure they become part of the solution

Implementing Open Innovation

• Horizon 2020 will support the full spectrum of activities throughout the research and innovation cycle – from knowledge and technology transfer to large scale demonstration actions, leading to scalable solutions for Europe and beyond.

Implementing Open Innovation in Horizon 2020

Consider the benefits and risks of Open Innovation in EU health research

Collaborative projects

Simpler

• Simpler programme architecture, a single set of rules

• Easy to use cost reimbursement model: one unique funding rate

• Less paperwork in preparing proposals

• Reduce time to grant by 100 days

More inclusive

• More support for innovation and activities close to the market

• Strong focus on creating business opportunities

Special support for SMEs

• ~5 billion EUR in H2020

• Inspired by the US model "SBIR"

• Challenge driven, bottom up

• A single company can be funded

• 3 phases / 3 entry points:

• Concept and feasibility assessment

• R&D, demonstration, market replication

• Commercialisation

In the pipeline: public-private partnership for innovative health

research

Based on the successes of the Innovative Medicines Initiative (IMI)

Legislative proposals only after Horizon 2020 approval

Organisation and structure to be defined

Your view matters (public consultation closed on 4th October)

Thank you!